Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Early-stage classical Hodgkin lymphoma (stage I to II), drawn from the whole corpus: 12 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Radiotherapy omission trades a few percent more relapses against late harms that take decades to appear.
Also on OnCo: Treatment journeys · Survivorship planner.
Bleomycin lung toxicity and doxorubicin cardiotoxicity persist even in short regimens.
Background: Quality of life. Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Whether PD-1 antibodies can replace chemotherapy in early disease is untested.
Older patients with early disease tolerate ABVD poorly and have no dedicated standard.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Omitting radiotherapy after a negative interim scan cost 7.
Switching a positive interim scan to escalated BEACOPP raised five-year progression-free survival from 77.
A milestone in how this cancer is treated.